Recently, our laboratory and others showed that either Olaparib or PARP1 gene silencing activated STAT3 by increasing STAT3 phosphorylation through dePARylation in cancer cells and immune cells, partially counteracting the tumor cell-killing efficacy of Olaparib (5, 6). This evidence concerns the gene PARP1 and neoplasm.